Veracyte, Inc. (VCYT) Guidance & Earnings Results

On 2026-07-30 Veracyte, Inc. raised guidance: "FY26 total revenue raised to $590-596M (14-15% growth) from $582-592M (13-14% growth); testing revenue raised to $576-582M (17-18% growth) from $570-580M; Adj EBITDA margin…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VCYTVeracyte, Inc.Follow VCYT — free

Diagnostics & Research · Healthcare

—

Price chart with a free account

Market cap: 3.9B
P/E TTM: 34.2
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
30 Jul 26	Raised	FY26 total revenue raised to $590-596M (14-15% growth) from $582-592M (13-14% growth); testing revenue raised to $576-582M (17-18% growth) from $570-580M; Adj EBITDA margin >26% · full year
5 May 26	Raised	FY2026 total revenue guidance raised to $582-592M (13-14% growth) from $570-582M; testing revenue guidance raised to $570-580M (16-18% growth); adjusted EBITDA margin guidance raised to >26% from ~25% · full year
25 Feb 26	Raised	Exciting 2026 with new product launches · full year
12 Jan 26	Raised	FY2026 total revenue guidance $570M-$582M (10-13% growth), testing revenue guidance $559M-$569M (14-16% growth), adjusted EBITDA margin 25%
4 Nov 25	Raised	Total revenue guidance raised to $506M-$510M (from $496M-$504M); testing revenue to $484M-$487M (from $477M-$483M); adjusted EBITDA margin to >25% (from 23.5%). · full year
6 Aug 25	Raised	FY2025 testing revenue raised to $477-483M from $470-480M; FY2025 total revenue initiated at $496-504M; FY2025 adjusted EBITDA margin raised to 23.5% from 22.5% · full year

Veracyte, Inc. — questions

What guidance did Veracyte, Inc. give?: On 2026-07-30: "FY26 total revenue raised to $590-596M (14-15% growth) from $582-592M (13-14% growth); testing revenue raised to $576-582M (17-18% growth) from $570-580M; Adj EBITDA margin >26%"
When does Veracyte, Inc. report earnings?: Veracyte, Inc.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from Veracyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.